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Arsenic exposure through drinking water is well-associated with adverse cardiovascular 
outcomes, yet the pathophysiological mechanisms by which inorganic arsenic (iAS) induces 
these effects are largely unknown. Recently, an epidemiological study found that iAS 
exposure was associated with altered left ventricular geometry. Considering the possibility 
that iAS directly induces cardiac remodeling independent of hypertension, we investigated 
the impact of an environmentally relevant iAS exposure on the structure and function of 
male and female hearts. 
Methods and Results 
Adult male and female C56BL/6J mice were exposed to 615 μg/L NaAsO2 for eight weeks. 
Males exhibited increased systolic blood pressure via tail cuff photoplethysmography, left 
ventricular wall thickness via transthoracic echocardiography, and increased plasma atrial 
natriuretic peptide via enzyme immunoassay. RT-qPCR revealed increased myocardial RNA 
transcripts of Acta1, Myh7, and Nppa, and decreased Myh6, providing evidence of 
pathological hypertrophy in the male heart. Similar changes were not observed in females at 
the same eight-week timepoint supporting the existence of a cardioprotective mechanism, 
but we did observe evidence that this protective signaling is starting to decline. Further 
investigation elucidated the upregulation of Rcan1 with iAS exposure in male hearts. We also 
observed iAS to directly activate NFAT in HEK293 cells using a luciferase assay, indicating 








Overall, this investigation provides the first mechanistic link between an environmentally 
relevant dose of iAS and the induction of pathological hypertrophy in the heart. We also 
found that iAS directly activates calcineurin-NFAT signaling in vitro, in accordance with 
findings that highlight an association between iAS exposure and cardiac remodeling in 
populations with a low burden of cardiovascular risk factors. Chronic iAS exposure is 
widespread, and these results provide biological impetus for its removal from human 
consumption. 
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1.0 General Introduction 
Human need to meet the energy demands of physical exertion has evolutionarily selected the 
modern Homo sapiens cardiovascular system.1 Continuous circulation of oxygen, hormones, 
and nutrients throughout the body is achieved through its intricate coordination of heart, 
vasculature, and blood. Proper functioning of this system is dependent upon an unperturbed 
harmony, else an individual becomes pre-disposed to cardiovascular disease (CVD), the 
world’s leading cause of death.2 Traditionally, risk factors for CVD have been considered 
unisex and modifiable such that the notions of increasing physical activity and potassium 
intake, decreasing smoking and sodium intake, and adhering to dietary approaches to stop 
hypertension are recommended to the general public.3 However, an awareness that there 
exists a greater age-adjusted CVD mortality rate among males compared to premenopausal 
females has shifted clinical care to recognize sex-specific symptoms and promote their 
respective recommendations for disease prevention.4 Currently, environmental agents such 
as metals and air pollution are implicated in CVD etiology and pathogenesis.5 Growing 
evidence suggests that these exposures initiate and augment pathophysiological processes in 
a manner similar to that of traditional risk factors.5 Analogous to recent developments in 
understanding sex differences in CVD, investigation of the biological bases of environmental 
exposures’ potentially sex-disparate effects on health and well-being has become necessary. 
Exploration of the mechanisms by which inorganic arsenic exposure alters the structure and 






1.1 Heart Physiology 
Mammalians hearts are comprised of four distinct muscular chambers, two atria and two 
ventricles, which are divided into the functionally separate right and left sides of the heart; 
the right atrium and ventricle pump blood from the inferior and superior vena cava to the 
pulmonary arteries for oxygenation, and the left atrium and ventricle pump this oxygenated 
blood from the pulmonary veins to the aorta for systemic circulation. Four distinct valves 
isolate and ensure unidirectional flow between atrial chambers and their respective ventricles 
(the tricuspid and mitral valves for the right and left heart, respectively), as well as ventricular 
chambers and their respective arterial systems (the pulmonary and aortic valves). Opening 
and closing of all such valves is primarily dictated by the pressure gradient across the valve, 
which becomes a concern, for example, when systemic blood pressure is consistently outside 
of the normal physiological range. Hearts are primarily composed of cardiac muscle cells, 
termed cardiomyocytes; these cells are electrically excitable and generate action potentials to 
orchestrate chamber contraction based on both time- and voltage-dependent changes in 
transmembrane ion channels. Cardiomyocytes differ in their action potential characteristics 
based on their role in (1) regulating the heart rate as pacemaker cells, (2) synchronizing the 
different regions of the heart in the Purkinje network, (3) contracting the atrial cambers, or 
(4) contracting the ventricles. Following cardiomyocyte depolarization in all contracting cells, 
potassium efflux is balanced by an influx of calcium ions through L-type calcium channels, 
the duration of which depends on the role of the cell. Calcium then enters cardiomyocytes 
and induces further calcium release from the sarcoplasmic reticulum; these calcium ions 
diffuse through myofilament lattice and bind to an inhibitory troponin protein, which allows 
actin-myosin interactions, resulting in contraction. Considering that the rhythmic contraction 






intricately regulated not only by the filling and ejection of blood but also by electrical signals 
and the cycling of intracellular calcium, the dysfunction of any such part may result in an 
array of cardiac pathologies. 
1.1.1 Cardiovascular Disease 
Pathologies related to the cardiovascular system constitute the largest global burden of 
disease.6,7 Among these pathologies, coronary heart disease, high blood pressure, and heart 
failure contribute to the majority of CVD-attributable deaths.8 Coronary arteries are blood 
vessels that supply the myocardium, and as such, coronary heart disease is characterized by 
the insufficient delivery of oxygenated blood to the heart—also termed ischemic heart 
disease. Heart failure, on the other hand, is broadly characterized by abnormalities in the 
myocardium that may impair pressure development or relaxation, resulting in either a 
preserved or reduced amount of blood ejected from the heart, termed ejection fraction. 
Beyond the palpable adverse health effects inflicted on the individuals experiencing these 
pathologies, CVD results in a significant economic burden by not only generating 
tremendous healthcare costs, but also by decreasing worker productivity. 
1.1.2 Sex Differences in Heart Physiology and Pathology 
Fundamental heart functions are maintained across both biological sexes, defined by 
chromosomal composition, but there exist several recently appreciated differences in cardiac 
physiology and CVD pathology between males and females. 
Sex differences in the heart begin to manifest at puberty as the concentration of sex steroids 
and the expression of their respective receptors begin to increase.9 Estrogen and testosterone 






Classically, estrogen and its major circulating compound, 17beta-estradiol, can function by 
binding to nuclear receptors, estrogen receptor alpha and estrogen receptor beta, and acting 
as a transcription factor complex to then directly regulate the expression of target estrogen-
responsive genes; the estrogen-receptor complex can also interact with other classes of 
transcription factors to regulate the expression of genes without estrogen-responsive 
elements in their promoter regions.10 Testosterone can similarly bind nuclear receptors to 
modulate genomic actions; it is worth noting here that testosterone may be converted to 
estrogen by aromatase. However, estrogen can alternatively function by interacting with 
membrane receptors and signaling cascades to modulate non-genomic actions.10 
Nonetheless, both classes of sex steroids are thought to construct their respective sex-based 
differences in heart physiology and CVD outcomes. 
Pre-menopausal females generally exhibit better cardiac function at baseline compared to 
age-matched males.9 Anatomically, male hearts have greater mass compared to female hearts, 
and this is mediated not by an increase in the number of cardiomyocytes, but by an increase 
in cardiomyocyte size—hypertrophy—throughout the male heart.9 Additionally, studies on 
male and female response to physiological cardiovascular stress, such as exercise, do not find 
a difference in cardiac output, which is a function of heart rate and the amount of blood 
pumped with each heartbeat, termed stroke volume.11,12 Rather, sex differences in this 
context manifest in the respective mechanism of increasing cardiac output; whereas males 
increase their total peripheral vascular resistance, females predominantly increase their heart 
rate.13 Furthermore, the female cardiovascular system is uniquely equipped to increase 
cardiac output and decrease blood pressure to meet the metabolic needs of pregnancy.14 
Beyond a distinguished response to physiological events, females are also found to have 






counterparts. Pre-menopausal females have a lower prevalence of ischemic heart disease and 
heart failure compared to age-matched males, and this is thought to be partially attributable 
to estrogen.15,16 Estrogen has been shown to activate protective mechanisms involving 
calcium handling, which regulates cardiac electrophysiology and contraction; 
phosphoinositol 3-kinase (PI3K) and Akt, which regulate cell survival pathways; and nitric 
oxide (NO), which regulates signaling in cardiomyocytes and endothelium.9 Molecular sex 
differences that extend into cardiovascular redox biology continue to be unraveled, 
highlighting the importance of accounting for sex and hormonal status in studying the heart 
in health and disease.17 
1.2 Cardiac Hypertrophy 
1.2.1 Physiological Hypertrophy and PI3K-Akt Signaling  
Cardiac remodeling describes post-gestational alterations in the structure of the myocardium. 
Females undergo cardiac remodeling during pregnancy, for example, to enlarge the ventricles 
of the heart and facilitate an increase in cardiac output. Repetitive endurance exercise can 
also induce hypertrophic growth of the myocardium; this occurs as a compensatory, adaptive 
mechanism to counterbalance the increased ventricular wall tension, induced by elevated 
blood pressure, and meet metabolic demands. During such growth, termed physiological 
hypertrophy, there is an increase in cardiac mass as a result of cardiomyocyte enlargement in 
both width and length, as well as a proportional expansion of the capillary network supplying 
the myocardium via angiogenesis, such that normal cardiac function is maintained. 
Physiological hypertrophy is coordinated by an array of molecular responses to promote 






control. Signals from mechano-transduced forces and growth hormones, such as insulin, 
trigger cell survival pathways, including the PI3K and Akt cascade. Insulin binds to the 
insulin receptor, which is a tyrosine kinase that phosphorylates insulin receptor substrate 
adaptor proteins to activate PI3K, generating phosphatidylinositol 3,4,5-triphosphate (PIP3) 
and thereby phosphorylating and activating Akt to coordinate protein synthesis and cell 
growth. Moreover, PI3K signaling exhibits crosstalk with the expansive mitogen-activation 
protein kinase (MAPK) pathway, which can coordinate transcriptional regulation to promote 
physiological hypertrophy. Insulin-like growth factor 1 (IGF1), which is synthesized and 
secreted in the heart upon growth hormone stimulation, can act through its own receptor to 
also canonically activate the Akt and MAPK pathways. Several studies have demonstrated 
that the promotion of Akt expression and activation by transgenic alteration of upstream 
mediators such as PI3K or IGF1 was responsible for myocardial growth without cardiac 
dysfunction.18–20 Considering that several pathways share Akt as a downstream effector of 
adaptive processes, levels of Akt gene and protein expression as well as phosphorylation, 
serve as strong markers of physiological hypertrophy. Beyond PI3K and Akt signaling, the 
IGF1 receptor can activate a heterotrimeric G protein subunit to activate phospholipase C 
(PLC) and generate inositol 1,4,5-triphosphate (IP3) to induce the release of calcium from 
the endoplasmic and sarcoplasmic reticulum and facilitate cardiomyocyte contraction. Taken 
together, these processes, among others, direct an adaptive response in cardiac performance 
to meet the structural and metabolic demands of physiological hemodynamic stress.  
1.2.2 Pathological Cardiac Hypertrophy and Calcineurin-NFAT  
Although cardiac remodeling may be adaptive as described, adverse stress such as ischemic 






the heart. Chronic hypertension, which describes a consistently elevated blood pressure 
exceeding a defined range, confers greater pressure on the myocardium that it must 
overcome in order to proceed with each circulatory pump; hypertensive left ventricular 
hypertrophy may thus result in order to meet this demand. However, in this pathological 
context, cardiomyocyte growth is asymmetric and exceeds the capacity of the capillary 
network supplying the myocardium. Geometrically, pathological hypertrophy may either be 
concentric, characterizing an increased wall thickness and decreased ventricular chamber as a 
result of cardiomyocyte expansion in thickness rather than length, or eccentric, describing a 
dilated ventricular chamber as a result of cardiomyocyte expansion in length. Whereas an 
adaptive response following Laplace’s law accounts for an increase in ventricular pressure by 
an inversely proportional increase in ventricular wall thickness, eccentric remodeling instead 
increases the cavity radius, proportional to ventricular wall stress. Although concentric 
hypertrophy can progress into eccentric hypertrophy, or vice versa via clinical intervention 
targeting mechanical unloading, cardiac dysfunction manifests in both maladaptive classes as 
a result of altered calcium handling, sarcomere disorganization, metabolic dysregulation, 
fibrosis, and cardiomyocyte death.21 Appropriately, pathological cardiac hypertrophy is 
characterized as an independent risk factor for adverse cardiovascular events such as 
arrhythmia, ischemic heart injury, and heart failure.22–24 Experimentally, hypertrophied 
myocardium exhibit increased sensitivity to biochemical and metabolic changes during 
ischemia-reperfusion injury in the heart and decreased recovery of contractile function 
afterwards.25,26 Pathological cardiac hypertrophy thus not only increases the susceptibility of 
the myocardium to ischemia-reperfusion injury but also augments the injurious response.25 
Although there exist many molecular mechanisms that mediate myocardial hypertrophy, 






pathway of significant interest.27 Calcineurin is a calcium-dependent serine/threonine 
protease that can serve as a major pro-hypertrophic signaling molecule in the myocardium.28 
Physiologically, calcineurin associates with calcium-bound calmodulin; an elevated 
concentration of calcium therefore increases its enzymatic activity, dephosphorylating NFAT 
and inducing its nuclear translocation.28,29 However, upon constitutive activation in mouse 
cardiomyocytes, calcineurin induces genetic, molecular, and phenotypic hallmarks of 
hypertrophied myocardium and heart failure, which are rescued both in vivo and in vitro by 
pharmacological calcineurin inhibition.30 Considering that calcineurin-NFAT activation is 
shown to be both necessary and sufficient in the development of myocardial hypertrophy, it 
serves as an integral pathway to probe in investigations of cardiac remodeling.31 
1.2.3 Fibrosis of the Heart 
Pathological hypertrophy may also result from an increase in nonmyocytes within the heart 
via cardiac fibrosis. Endothelial cells and cardiomyocytes are the predominant cell types 
found in the normal heart, and fibroblasts constitute a marginal fraction of nonmyocytes.32 
Pathological stimuli, however, can induce myocardial fibrosis, which is defined by an 
increase in extracellular matrix within the heart.21 Cardiac fibrosis not only increases the 
stiffness of the heart, which impedes contractility, but it also results in altered heart 
architecture and cardiac dysfunction. Currently, there are no molecular markers specific to 
cardiac fibroblasts, partially a result of their heterogeneous origins.33 However, transforming 
growth factor beta (TGFβ) is a well-characterized mediator of cardiac fibrosis. Three 
isoforms of TGFβ (TGFβ I, II, and III) are found in mammals, and these generally bind to 
their respective receptor to activate the Smad2/3 pathway and promote fibrosis of the 






type II receptor, recruiting Smad 2 and Smad 3, which form a heterotrimer with Smad 4 to 
then translocate into the nucleus and regulate target genes; this increases the gene expression 
of extracellular matrix molecules, including collagen and fibronectin, promoting extracellular 
matrix deposition in the heart.33 Cardiac fibrosis is particularly characteristic of an increase in 
the accumulation of both type I and type III collagen.34,35 Once these pro-collagen chains are 
secreted from myofibroblasts within the heart, they are processed and assembled into fibrils, 
and then crosslinked; it is this crosslinked collagen that has been shown to be associated 
with both altered cardiac remodeling and cardiac dysfunction within the pathologically 
hypertrophied heart.36–38 As such, type I and type III collagen serve as critical markers of 
pathological hypertrophy mediated by TGFβ activation and fibrosis. 
1.2.4 Nitric Oxide Signaling in Cardiac Hypertrophy 
NO is a signaling molecule that’s primarily produced by endothelial NO synthase (eNOS), 
but also by inducible NOS (iNOS) and neuronal NOS (nNOS) isoforms in the heart.39 
Exercise is known to stimulate beta adrenergic receptors in endothelial cells, phosphorylating 
and activating eNOS to generate NO and promote vasodilation and angiogenesis in 
physiological hypertrophy.40–42 As such, NO signaling adds a dimension of complexity to the 
pathological calcineurin-NFAT pathway. Pharmacological and genetic inhibition of eNOS-
mediated NO generation in mice is shown to increase cardiomyocyte size and induce 
myocardial hypertrophy, fibrosis, and dysfunction, all of which are abrogated by restorative 
eNOS therapy.43 Furthermore, overexpression of the gene encoding eNOS, NOS3, is shown 
to attenuate hypertrophy in addition to its cardioprotective effects against pressure 
overload.43,44 Anti-hypertrophic effects of NO are shown to manifest by its cGMP-mediated 






molecular and phenotypic markers of hypertrophy in cardiomyocytes and myocardium.45 
Although PKG deletion neither potentiates nor alters the degree of hypertrophy compared 
to that induced by either pharmacological agent or surgical intervention, its negated role in 
hypertrophic development suggests that PKG has a limited role in hypertrophy upstream of 
its anti-hypertrophic effects by NFAT inhibition.46 Altogether, interplay between the NO-
cGMP and calcineurin-NFAT signaling pathways must be considered in an investigation of 
remodeling-induced alterations in the context of cardioprotection. 
1.3 Myocardial Ischemia-Reperfusion Injury 
Restoration of blood flow to the heart following a period of circulatory restriction/occlusion 
can induce ischemia-reperfusion (I/R) injury in the muscle tissue of the heart—the 
myocardium.47 Ischemia, the first component of I/R injury, generates oxygen debt, which 
inhibits oxidative phosphorylation; this depletes adenosine triphosphate (ATP) and induces a 
cascade of biochemical and metabolic alterations with a shift towards anaerobic respiration 
that increases cytosolic calcium, decreases cardiomyocyte contractility and mitochondrial 
membrane permeability, and induces cell swelling and necrosis.48,49 Reperfusion, though 
shown to reduce ischemic infarct size by 40% in animal models in part by reactivating the 
electron transport chain and restoring physiological pH, also has deleterious effects that are 
mediated by calcium and reactive oxygen species (ROS), resulting in ventricular arrhythmia, 
contractile dysfunction, microvascular obstruction, and/or lethal cardiomyocyte injury.49–51 
Cardioprotection against I/R injury refers to the reduction of these consequences and is 
shown to act endogenously in vivo among premenopausal females in part by estrogen and 
nitric oxide (NO) signaling pathways, which contribute to their decreased risk of CVD.52–54 






to differ by sex, investigation of these toxicants’ effects on sex-dependent cardioprotective 
signaling pathways is warranted.55 
1.3.1 Nitric Oxide Signaling in Ischemic Heart Injury and Cardioprotection 
NO widely regulates cardiovascular homeostasis and plays a critical role in reducing I/R 
injury.54,56 S-nitrosylation (SNO), for example, is an NO-dependent post-translational 
modification that can shield thiol groups from oxidation and modulate a variety of proteins 
including estrogen receptors and calcium channels to confer cardioprotection.56–59 Cyclic 
guanosine monophosphate (cGMP) is another ubiquitous intracellular second messenger 
that can be endogenously synthesized by the binding of NO with soluble guanylyl cyclase 
(sGC) in the cytosol.60 Stimulation of NO production via eNOS increases cGMP production 
and activates protein kinase G (PKG), which has a number of targets that can modulate 
myocardial contractility.61 NO-activated PKG can also activate protein kinase C, which is 
shown to open a mitochondrial ATP-dependent potassium channel that can consequently 
confer mitochondrial-mediated cardioprotection.62,63 Separately, NO-activated cGMP can 
increase phosphodiesterase 2 activity, which inhibits protein kinase A, decreasing 
phospholamban and sarcoendoplasmic reticulum calcium ATPase activities; this increases 
calcium sequestration, decreases calcium cycling, and reduces cell death, promoting 
cardioprotection.60 Altogether, the NO-cGMP signaling axis presents a pathway of particular 
interest in investigations of altered susceptibilities to I/R injury. 
1.4 Environmental Exposures and Cardiovascular Disease 
Despite advancements in its treatment and prevention, CVD remains the world’s leading 






implicated in CVD etiology and pathogenesis.5,64 Air pollution, for example, has jumped to 
being the third leading risk factor for CVD mortality after extensive investigation into its 
effects on the cardiovascular system.7,65,66 Considering the possibility that the prevalence and 
mortality of CVD continues to grow in spite of clinical management and intervention, it is 
possible that part of the challenge in preventing its escalation results from a fundamental gap 
in the understanding of the complex interplay between chronic environmental exposures and 
the cardiovascular system.67 
1.4.1 Exposure to Inorganic Arsenic and Associated Cardiac Pathologies 
Growing evidence highlights arsenic as a potential modifier of cardiovascular structure and 
function.5 Arsenic is a naturally-occurring metalloid that enriches the earth’s crust.68 Leach 
into groundwater in addition to that accumulated from anthropogenic sources constitutes a 
majority of its presence in groundwater and foods such as rice and grains.69 Human exposure 
to arsenic occurs predominantly via ingestion of contaminated drinking water, in which 
arsenic exists in an inorganic form (iAS) in either a trivalent or pentavalent oxidation 
state.70,71 Following ingestion of contaminated drinking water, over 95% of the iAS is 
absorbed and then biotransformed into monomethylated (MMA) and dimethylated (DMA) 
metabolites, each associated with different health effects.71 Ecological studies correlate iAS 
exposure among large populations in several countries with a dose-dependent increase in the 
risk and incidence for CVD.72 Exposure to iAS is also epidemiologically and experimentally 
associated with other risk factors for CVD such as diabetes, abnormal electrocardiography, 
and hypertension. As(III) but not As(V) is shown to alter cardiovascular function by 
reducing the amount of blood pumped from the left ventricle in rat and rabbit models.73 






blood pressure, ventricular wall thickness, and left ventricular mass in female mice; this 
increase in blood pressure and heart size is also corroborated by cross-sectional studies in 
human populations.74–76 Separately, iAS exposure is associated with a prolonged period of 
repolarization after each cardiac cycle in females but not in males as evaluated by 
electrocardiography (ECG) in a substantial prospective cohort study, highlighting certain 
sex-disparate effects at the population level.77 Seeing as iAS exposure is also implicated in the 
reduction of NO levels by way of eNOS dysfunction, which may induce an array of 
alterations in cardiovascular physiology and signaling as described, an investigation into the 
effects of iAS on ischemic heart injury is justified.78 
1.4.2 Inorganic Arsenic Exposure and Ischemic Heart Injury 
Recent findings from this laboratory show that exposure to iAS at 1000 parts per billion 
(ppb or μg/L) for four weeks exacerbates I/R injury in female mouse hearts and attenuates 
injury in that of males (Fig. 1a, b).79 Echocardiography also reveals myocardial enlargement 
in iAS-exposed female hearts (Fig. 1c).79 Although iAS-exposed male hearts are not 
morphologically altered, they exhibit an increase in eNOS phosphorylation at serine-1177, an 
activating site of the cardioprotective enzyme (Fig. 1d).79 Considering that the structural 
remodeling of female hearts manifested independently of eNOS phosphorylation or 
expression, these results suggest that iAS exposure induces sex-disparate effects and 
modulates susceptibility to IHD by targeting distinct sex-dependent pathways, laying ground 







Figure 1. Summary of findings following a four-week, 1000 ppb iAS exposure in mice. Post-
I/R infarct size (a) increases with exposure in female hearts but (b) decreases in males. (c) 
Left ventricular mass shows a modest increase with iAS in females. (d) Phosphorylation of 
eNOS at serine-1177, an activating site, is increased in males. 
1.5 Specific Aims 
Several studies provide evidence that myocardial I/R injury is increased by the male sex and 
attenuated by the female sex.80–84 Veenema et al. highlight a reversal in this response 
following a four-week exposure to iAS via drinking water in mice.79 However, 
epidemiological studies utilizing large, chronically-exposed populations across several 
countries do not corroborate an iAS-induced sex difference in the incidence of ischemic 
heart disease (IHD), suggesting that the observed cardioprotection is not maintained in the 
long-term.85 Because modest sex-disparate effects manifested with a narrow window of 
exposure, an extension of the model is proposed to elucidate potential mechanisms through 
which iAS modulates susceptibility to I/R injury. We therefore hypothesized that an eight-
week exposure to 1000 μg/L iAS induces cardiac remodeling and exacerbates myocardial 







1.5.1 Evaluate the impact of iAS exposure on I/R injury and cardioprotection 
Mechanistically, it is possible that an increased phosphorylation of eNOS at four weeks of 
exposure in males led to an upregulation of the previously described cGMP-PKG signaling 
pathway, which is not only independently cardioprotective but also suppressive of cardiac 
hypertrophy. Because an iAS-induced reduction of hypertrophy or I/R injury is not 
observed at the epidemiological level, it is hypothesized that an extension of the exposure 
model abrogates cardioprotection and activates additional pathways inducing myocardial 
pathologies. Following the overarching hypothesis, it is expected that an eight-week iAS 
exposure will increase myocardial infarct size and decrease functional recovery of the heart 
following I/R in both sexes. Compared to pre-ischemic values, post-ischemic left ventricular 
developed pressure and rate pressure product are expected to decrease with iAS exposure. 
Additionally, infarct size is expected to increase with iAS exposure in both sexes. 
Four-week exposure to iAS is shown to increase eNOS phosphorylation in males and not in 
females, which may lead to increased NO synthesis and promote subsequent attenuation of 
I/R injury early-on.79 However, it is possible that this male cardioprotection is a quirk of 
utilizing an animal model that can better metabolize iAS for only a brief exposure period. An 
extended exposure to iAS is thus hypothesized to downregulate eNOS in both sexes and 
abrogate cardioprotection. 
1.5.2 Define the implications of iAS exposure on remodeling of the myocardium 
Results from a four-week exposure to 1000 μg/L iAS suggest modest cardiac enlargement in 
females.  As such, it is also hypothesized that eight weeks of iAS exposure induces greater 






Hypertrophy of the heart is defined by altered cardiac structure and hemodynamics. 
Characterization of these properties will test the hypothesis that exposure to iAS increases 
blood pressure and induces cardiac remodeling. Exposure to iAS is expected to increase 
blood pressure and the heart weight to tibia length ratio. Additionally, histology is expected 
to reveal fibrosis in iAS-exposed hearts. Considering that calcineurin-NFAT signaling has a 
necessary and sufficient role in the development of cardiac hypertrophy, quantification of 
the expression and activity of this pathway will test the hypothesis that exposure to iAS 
upregulates calcineurin-NFAT signaling to promote pathological remodeling of the heart. 
1.5.3 Overall study goals and significance 
Ischemic heart disease (IHD) remains the world’s leading cause of death.86 Environmental 
agents such as metals and air pollution are increasingly implicated in the development of 
CVD, including IHD.5 Although there exists a greater age-adjusted IHD mortality rate 
among males compared to that of premenopausal females, exposure to iAS via drinking 
water for four weeks is shown to reverse the expected, exacerbating ischemia-reperfusion 
(I/R) injury in the female mouse heart while lessening it in that of males.79,87 Considering that 
these sex-disparate effects are not observed at the ecological level among chronically-
exposed populations, the proposed study seeks to utilize an extended eight-week exposure to 
observe a hypothesized (Aim 1a) increase in susceptibility to myocardial I/R injury, (Aim 1b) 
downregulation of cardioprotective signaling pathways, (Aim 2a) increased cardiac 
remodeling, and (Aim 2b) upregulated hypertrophic signaling pathways in both sexes, 
thereby serving as a potential mechanism by which chronic exposure to iAS modulates 






Should phenotypic results indicate increased I/R injury and cardiac remodeling in males and 
females, this study may be the first to highlight that iAS exposure alters susceptibility to I/R 
injury by inducing cardiac remodeling. Additionally, this long-term exposure may illuminate 
molecular changes in NO signaling pathways that were previously unobserved due to a brief 
period of exposure. Regardless of whether data supporting the hypotheses are observed, 
results from the proposed experiments are essential to further define the effects of iAS 
exposure on the myocardium. Findings from this study will be useful in investigating sex-
dependent mechanisms by which iAS promotes other CVD pathologies, which may, in the 
long-term, lead to the development of clinical and public health strategies to prevent the 







INORGANIC ARSENIC INDUCES SEX-DISPARATE CARDIAC 
HYPERTORPHY 
2.0 Introduction 
Cardiovascular disease (CVD) remains the leading cause of death throughout the world.6,7 
Traditionally, risk factors for CVD have been considered personally modifiable such that the 
notions of increasing physical activity, avoiding tobacco smoke, and adhering to dietary 
approaches to stop hypertension are recommended to the general public.88 However, 
growing evidence implicates environmental agents such as metals and air pollution in CVD 
etiology and pathogenesis.5,64 Considering that the latter has jumped to the third leading risk 
factor in the global burden of disease, behind high blood pressure and tobacco smoke, the 
modulation of CVD and its risk factors by environmental agents must be studied.7,65,66 
Arsenic is a naturally-occurring metalloid found in the Earth’s crust that leeches into 
drinking water, which is the primary mode of human exposure.71 The World Health 
Organization lists arsenic as one of ten chemicals of major public health concern, 
recommending a maximum limit of 10 μg/L in water supplies. However, the levels of 
arsenic in drinking water, existing as inorganic arsenic (iAS), have been found to exceed 1000 
μg/L in some parts of the United States and 5000 μg/L in other parts of the world.68,71 
Chronic iAS exposure has been linked to several disease states, particularly diabetes, CVD, 
and cancer.89,90 Although exposure to iAS is well-associated with adverse CV outcomes, the 






Previous findings from our laboratory showed that a four-week exposure to 1000 μg/L iAS 
was sufficient to exacerbate ischemic injury in female mouse hearts but not in males, 
highlighting sex-dependent cardiac remodeling as a potential mode of action.79 Additionally, 
recent findings from the Strong Heart Study show that individuals exposed to iAS exhibit 
altered left ventricular geometry.93 Considering that sex-disparate effects of iAS have not 
observed at the ecological level in chronically-exposed populations, we utilized an extended 
model of exposure in the current study to investigate the effects of iAS on myocardial 
structure and function in male and female hearts. We report for the first time that exposure 
to an environmentally relevant dose of iAS induces sex-dependent pathological hypertrophy 
of the heart, in part by upregulating the calcineurin-NFAT signaling pathway. As such, these 
findings confer mechanistic significance to the detrimental impact of iAS exposure on 
cardiovascular health, highlighting the need for its removal from human consumption. 
2.1 Methods 
2.1.1 Animals and Exposure Protocol 
Seven-week-old male and female C57BL/6J wildtype mice (Jackson Laboratory, Bar, 
Harbor, ME) were housed (5 mice per cage) under pathogen-free conditions and maintained 
on AIN-93G chow (Research Diets, New Brunswick, NJ) and Nestle Pure Life water (Nestlé 
Waters North America, Stamford, CT) for one week prior to iAS exposure. Both the water 
and the chow are reported to have undetectable iAS levels, and the water was re-validated via 
inductively coupled plasma mass spectrometry (ICP-MS; Agilent 7500ce Octopole; Agilent 
Technologies, Santa Clara, CA) to have an iAS concentration less than its 0.16 μg/L limit of 
detection.94,95 Following a one-week pre-exposure acclimation period, mice received water 






libitum for eight weeks; water and chow were refreshed every two to three days to minimize 
oxidation, and bedding was changed weekly. iAS exposure was further confirmed by the 
detection of iAS in urine samples via ICP-MS in exposed groups and the lack thereof in 
control groups (data not shown). Mice were anesthetized prior to subsequent procedures via 
intraperitoneal ketamine-xylazine injection (90 mg/kg ketamine, Hofspira, Lake Forest, IL; 
10 mg/kg xylazine, Sigma Aldrich, St. Louis, MO), confirmed for adequacy via toe pinch. All 
animal work in this investigation conformed to the Guide for the Care and Use of 
Laboratory Animals published by the National Institutes of Health (NIH; Publication No. 
85-23, Revised 2011) and was approved by the Institutional Animal Care and Use 
Committee of Johns Hopkins University. 
2.1.2 Blood Pressure Measurement 
Mice were acclimated to a tail-cuff pressure transduction apparatus (BP-2000 Blood Pressure 
Analysis System; Visitech Systems, Apex, NC) for one week prior to the onset of exposure 
and data collection in order to minimize systolic standard deviation and ensure 
reproducibility. Mice were restrained by opaque, open-bottomed rodent holders (BP-MH0; 
Visitech Systems, Apex, NC) that facilitated breathing and limited light exposure to calm the 
animal and reduce stress; the platform was preheated and maintained at 38°C in the dark 
under a laminar flow hood, and the tails were secured to the platform with surgical tape (3M 
Transpore Surgical Tape; 43149; 3M Company, Maplewood, MN) to minimize movement. 
Twenty experimental measurements were taken on each mouse each session, preceded by 
five preliminary measurements which allowed the animals to become accustomed to the tail 
cuff inflation and restraint. Briefly, the instrument reads and determines pulse through the 






blood pressure by analyzing the variation in light transmitted through the tail; during systole, 
vessels dilate and scatter light with each pressure wave, while the reverse occurs during 
diastole. As such, diastolic pressure was recorded when the cuff’s pressure of occlusion 
caused the waveform amplitude (vessel dilation) to decrease, and systolic pressure was 
recorded when the occlusion pressure was sufficient to completely collapse the waveform, 
thus not causing any further dilation. Waveforms were monitored for appropriate amplitude 
during each of the twenty readings, and all values were averaged for each mouse each day, 
excluding outliers as categorized by a systolic pressure beyond 1.75 standard deviations from 
the mean. Measurements were taken at the same time twice a week throughout the duration 
of the exposure, as well as every day of the first, fourth, and eighth weeks. 
2.1.3 Transthoracic Echocardiography 
Transthoracic echocardiography was performed in conscious mice using a Vevo 2100 system 
with a 40-MHz linear transducer (FUJIFILM; VisualSonics, Toronto, ON, Canada) as 
described. M-mode echocardiogram was acquired from the short-axis view of the left 
ventricle at the level of the mid-papillary muscles and at a sweep speed of 200 mm/s. From 
this axis view of the left ventricle, the following cardiac parameters were measured: left 
ventricular anterior wall thickness at end diastole (LVAWd), left ventricle internal diameter 
at end diastole (LVIDd), and left ventricle posterior wall thickness at end diastole (LVPWd). 
Percent fractional shortening (FS), percent ejection fraction (EF), and left ventricular mass 
(LV mass) were extrapolated from these parameters as measures of cardiac contractility and 
left ventricular morphology; these indices were derived from the following equations: FS 
(%) = [(LVIDd – LVIDs)/LVIDd] × 100, EF (%) = [(LVId2 – LVIDs2)/LVIDd2] × 100; 






specific gravity of the myocardium. Volumes at end-systole (Vs) and end-diastole (Vd), 
stroke volume (SV), and EF were estimated using the Simpson’s method and the two-
chamber view of the heart on long axis as well as the short axis. All echocardiography values 
were simultaneously generated/calculated using the LV trace function (Vevo 2100 Software). 
2.1.4 Inorganic Arsenic Measurement 
Samples of iAS-solubilized water, control water, and urine from each mouse was taken at the 
six-week timepoint using hydrophobic sand (Labsand, Braintree Scientific, Braintree, MA) 
and stored (−80°C) until analysis. Water and urine samples were blinded and analyzed by an 
independent laboratory. Briefly, samples (50 μL) were diluted into HNO3 (2%) and HCl 
(0.5%) solution. Calibration curves for arsenic were built using a standard solution (Multi-
element Aqueous CRM, QC Standard 21; VHG Laboratories, Manchester, NH). Ten μg/L 
(vol/vol) of internal standard (CPI International, Santa Rosa, CA) was added to samples and 
calibration curves to control for potential drifts in the signal. Arsenic concentrations were 
then measured using inductively coupled plasma mass spectrometry (Agilent 7500ce 
Octopole inductively coupled plasma mass spectrometer, ICP-MS; Agilent Technologies, 
Santa Clara, CA). The limit of detection was 0.16 μg/L for arsenic. Samples with iAS 
concentrations below the limit of detection were substituted by the limit of detection divided 
by the square root of two. For quality control and assurance, 10% duplicates, 10% blanks, 
Seronorm Trace Elements Urine (Accurate, Westbury, NY), and replicate sample analysis at 







2.1.5 Langendorff Heart Perfusion 
Hearts from mice anesthetized by intraperitoneal ketamine-xylazine injection were excised, 
cannulated onto a Langendorff apparatus, and perfused retrogradely with Krebs-Henseleit 
buffer bubbled with oxygen (95%) and carbon dioxide (5%) under constant pressure (100 
cmH2O) and temperature (37°C). Buffer consisted of, in mmol/L: NaCl (120), KCl (4.7), 
KH2PO4 (1.2), NaHCO3 (25), MgSO4 (1.2), d-glucose (11), and CaCl2 (1.75); pH 7.4; this 
reflected most physiological components of blood, including sodium, potassium, glucose, 
and calcium, which allowed the isolated heart to spontaneously beat with perfusion.96 Hearts 
were subjected to either a five-minute perfusion, after which they were sectioned into two 
halves and snap-frozen under liquid nitrogen, or ischemia-reperfusion as follows. 
 
Figure 2. Overview of heart collection workflow. Hearts were perfused with Krebs-Henseleit 
buffer on a Langendorff apparatus. Hearts were then either subjected to I/R injury and 






2.1.6 Ischemia-Reperfusion Protocol 
Immediately after Langendorff cannulation, a water-filled, saran-wrap balloon connected to a 
pressure transducer (PowerLab, AD Instruments, Dunedin, New Zealand) was inserted into 
the left ventricle of an excised heart to monitor and record digitized heart rate (HR) and left 
ventricular developed pressure (LVDP); rate pressure product (RPP) was calculated from 
these parameters and used as another metric of cardiac contractile function. Following a 
twenty-minute period of equilibration, perfusion was stopped for twenty minutes to induce 
global myocardial ischemia, and afterwards, the heart was re-perfused for two hours. Post-
ischemic functional recovery and contractility at sixty minutes into reperfusion were 
expressed as a percentage of the pre-ischemic RPP and as a function of the change in LVDP 
over change in time (dP/dt), respectively. Following ischemia-reperfusion (I/R), hearts were 
perfused with triphenyltetrazolium chloride (TTC; 1%; 2 min), which is metabolized by 
intracellular dehydrogenases into a red pigment, staining viable cells and leaving the infarct 
white; hearts were then incubated (37°C, 20 min) in TTC solution and subsequently fixed in 
formalin solution (10%). Hearts were sectioned into five transverse parts, and the two sides 
of each section were imaged under a dissecting microscope (Nikon). Infarct size was 
analyzed by an investigator blinded to the treatment groups using ImageJ software (NIH, 
Bethesda, MD), quantifying infarcted myocardium as a function of total myocardial area in 
the section plane. 
2.1.7 Histology 
Sectioned, formalin-fixed hearts were paraffin-embedded and stained with either 
haemotoxylin and eosin (H&E) or Masson’s trichrome to visualize cell morphology and 






Baltimore, MD). Whole slides of Masson’s-stained, paraffin-embedded hearts were scanned 
(20X, Aperio ScanScope) by a facility blinded to the treatment groups (Oncology Tissue 
Services, Johns Hopkins Medical Institutions, Baltimore, MD). Digital slides were 
subsequently analyzed (Aperio ImageScope) using a standard positive pixel count algorithm 
(Positive Pixel Count v9.1, Aperio, Leica Biosystems) according to the following parameters, 
set to read blue pixels as positive and red as negative, categorizing the former into three 
intensity bins: hue value = 0.62, hue width = 0.40, color saturation threshold = 0.04, 
intensity threshold (upper limit) of weak positive pixels = 220, intensity threshold (lower 
limit) of weak positive pixels = 175, intensity threshold (lower limit) of medium positive 
pixels = 100, intensity threshold (lower limit) of strong positive pixels = 0, intensity 
threshold of negative pixels = -1. Positivity, representing the number of positive pixels over 
the total number of positive and negative pixels, is reported as a quantification of myocardial 
collagen. 
2.1.8 Plasma Enzyme Immunoassays 
Blood was drawn from the inferior vena cava using a heparin-coated syringe and collected in 
a tube with heparin (10 μL) immediately after excision of the heart. Blood was centrifuged 
(21,130 x g, 10 min, 4°C), plasma was collected, and the samples were stored (-80°C) until 
use. Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) were measured 
via enzyme immunoassay following manufacturer’s instructions (EIA-ANP and EIA-BNP, 







2.1.9 Heart Homogenate Preparation 
Hearts were homogenized with cell lysis buffer (1 mL, Cell Signaling Technology, Danvers, 
MA) supplemented with a protease-inhibitor cocktail (Cell Signaling Technology) in a hard 
tissue lysing kit (Precellys CK28 Lysing Kit, Bertin Instruments) under dry ice using a bead-
mill tissue homogenizer (2 × 30 sec cycles, 0°C, 7200 RPM; Precellys Evolution 24, Bertin 
Instruments). Supernatant was recovered as total crude homogenate, protein concentration 
was determined via Bradford assay, and total homogenate aliquots were stored (-80°C). 
2.1.10 Western Blot 
Samples (30 μg) were separated on a graduated Bis-Tris SDS-PAGE gel (4-12%, NuPAGE, 
Invitrogen, Carlsbad, CA) and transferred to a nitrocellulose membrane (Life Technologies, 
Carlsbad, CA). Every gel included two molecular weight markers for separate regions of 
interest (High Range Color-Coded Prestained Protein Marker, Cell Signaling Technology; 
and Novex Prestained Protein Standard, Thermo Fisher Scientific, Rockford, IL). For 
normalization against total protein, lysine residues were covalently labeled (No-Stain Protein 
Labeling Reagent, Invitrogen) following manufacturer’s instructions and visualized by 
fluorescence (Life Technologies). Membranes were blocked (1 hr) with bovine serum 
albumin (5% w/v; Sigma Aldrich) in tris-buffered saline with tween-20 (0.1%), and 
subsequently incubated (overnight, 4°C) with primary antibodies against p-Akt S473 (1:1000; 
4060S, rabbit, Cell Signaling Technology, Danvers, MA), t-Akt (1:1000; 4691S, rabbit, Cell 
Signaling Technology), p-eNOS S1177 (1:500; 9570S, rabbit, Cell Signaling Technology), p-
eNOS T495 (1:500; 9754S, rabbit, Cell Signaling Technology), t-eNOS (1:250; sc-376751, 
mouse, Santa Cruz Biotechnology, Dallas, TX), PKG-1 (1:1000; 3248S, rabbit, Cell Signaling 






(1:1000; 3114S, rabbit, Cell Signaling Technology). Membranes were then probed (1 hr) with 
the corresponding secondary antibody, either anti-rabbit (7074S; Cell Signaling Technology) 
or anti-mouse (sc-2005; Santa Cruz Biotechnology), and visualized by electrogenerated 
chemiluminescence (Life Technologies). Membranes were stripped (Re-Blot Plus Mild 
Solution, EMD Millipore, Temecula, CA) and re-probed as needed. Densitometry was 
assessed using ImageJ software (NIH) and normalized to total protein. 
2.1.11 RNA Isolation, Extraction, and cDNA Conversion 
Hearts were homogenized with TRIzol (1 mL, Ambion) in a hard tissue lysing kit (Precellys 
CK28 Lysing Kit, Bertin Instruments) under dry ice using a bead-mill tissue homogenizer (2 
× 30 sec cycles, 0°C, 7200 RPM; Precellys Evolution 24, Bertin Instruments). Chloroform 
(200 μL, Thermo Fisher) was added, and samples were subsequently shaken (30 sec), 
incubated (5 min, 25°C), and centrifuged (12,000 × g, 15 min, 4°C) for phase separation. 
RNA in the upper aqueous phase was carefully collected in a new centrifuge tube. Isopropyl 
alcohol (500 μL) was added, samples were incubated (10 min, 25°C), and centrifuged (12,000 
× g, 8 min, 4°C) for RNA precipitation. After discarding the supernatant, the RNA pellet 
was washed with ethanol (500 μL, 75% EtOH), centrifuged (12,000 × g, 10 min, 4°C), and 
air dried under a laminar flow hood (30 min). RNA was solubilized (100 μL, DEPC-treated 
water), concentration and purity (A260/A280 range 1.98 to 2.06) were obtained via 
spectrophotometry (1 mL sample, NanoDrop 100, Thermo Fisher), and integrity was 
confirmed via agarose (1%) gel electrophoresis (1X TBE (Tris base, boric acid and 
ethylenediaminetetraacetic acid (EDTA)) and 18S and 28S rRNA band visualization. RNA 
was subsequently converted to cDNA per manufacturer’s instructions (4368814, High-






reaction mix was prepared on ice, RNA (2 μg) was added, and the samples were run on a 
thermocycler (60 min, 37°C; 5 min, 95°C; held, 4°C; Applied Biosystems); cDNA was stored 
(-80°C) until use. 
2.1.12 Quantitative PCR 
Expression of mRNA transcripts was measured using a standard master mix (TaqMan Fast 
Advanced Master Mix) with the following validated probes (TaqMan, Applied Biosystems) 
on a thermocycler (2 min, 50°C; 2 min, 95°C; (1 sec, 95°C; 20 sec, 60°C) × 40), Applied 
Biosystems) in a 384-well plate: Acta1 (Mm00808218_g1), Akt1 (Mm01331626_m1), Col1a2 
(Mm00483888_m1), Col3a1 (Mm00802300_m1), Gapdh (Mm99999915_g1), Myh6 
(Mm00440359_m1), Myh7 (Mm00600555_m1), Nppa (Mm01255747_g1), Nppb 
(Mm01255770_g1), Rcan1 (Mm01213406_m1). Expression was determined using the ΔΔCT 
method and normalized to Gapdh, which did not change with iAS treatment in either sex. 
2.1.13 Electron Paramagnetic Resonance 
Briefly, flash-frozen heart tissue (~20 mg) was homogenized in phosphate buffered saline 
(PBS) containing 0.1 mM diethylene-24 triaminepentaacetic acid (DTPA) and protease 
inhibitor cocktail (pH 7.4; Roche Applied Science, Indianapolis, IN). Non-soluble fractions 
were removed by centrifugation (15,000 x g, 10 min, 4°C), and the homogenates were kept 
on ice and analyzed immediately. Stock solutions of 1-hydroxy-3-methoxycarbonyl-2,2,5,5- 
tetramethylpyrrolidine hydrochloride (CMH; Enzo Life Sciences, Farmingdale, NY) were 
prepared daily in nitrogen purged 0.9% (w/v) NaCl, 25 g/L Chelex 100 (Bio-Rad) and 
DTPA (0.1 mM) and kept on ice; the samples were treated with CMH (1 mM, 37°C, 2 min), 






electron paramagnetic resonance (EPR) spectrometer at room temperature. Instrument 
settings were as follows:  sweep width, 100 G; microwave frequency, 9.75 GHz; modulation 
amplitude, 1 G; conversion time, 5.12 ms; receiver gain, 2 x 103; number of scans, 16. EPR 
signal intensities were normalized with respect to the protein concentrations of the tissue 
homogenates as determined by Pierce BCA protein assay kit (Life Technologies). 
2.1.14 Cell Culture Protocol 
Human embryonic kidney 293 cells (HEK293, Invitrogen) were maintained (5% CO2, 37°C, 
humidified air) in Dulbecco's Modified Eagle Medium (DMEM) with glucose (4.5 g/L) and 
L-glutamine (Gibco) supplemented with fetal bovine serum (10% FBS, Sigma-Aldrich) and 
100 U/mL penicillin/100 μg/mL streptomycin (1% P/S, Gibco, Life Technologies). 
2.1.15 Cell Proliferation Assay 
HEK293 cells seeded in a 96-well plate (2 × 104 cells/well) were treated with sodium 
arsenite (0, 0.5, 1, 5, 10, 25, 50, and 100 μM in complete cell culture media, 37°C, 24hrs). 
MTT reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; 50 μL/well; 
ab211091, Abcam) was then added and the cells were incubated (37°C, 1h). MTT solvent 
(150 μL/well; ab211091, Abcam) was added and the plate was shaken (orbital shaker, dark, 
40 RPM, 10 min) to solubilize the formazan crystals; absorbance (590 nm) was promptly 
read. Cell proliferation is represented by optical density as a percent of the average control. 
2.1.16 NFAT Luciferase Assay 
HEK293 cells cultured in DMEM (10% FBS, 1% P/S, Thermo Fisher) to 70% confluence 






Plasmids expressing Renilla-luciferase (0.001 μg, Promega) and/or TRPC6 (0.2 μg) were 
transfected (Xfect Transcfection, Takara Bio USA, Mountain View, CA) as internal and 
positive controls, respectively. Transfected cells were exposed to sodium arsenite (0, 1, 5, 10 
μM in complete cell culture media, 37°C, 24hrs). Cell lysate was then extracted using passive 
lysis buffer according to manufacturer's instructions (Promega), and luciferase activity 
measured by Dual-Luciferase Reporter Assay (Promega). 
2.1.17 Statistical Analysis 
Sample sizes of mice and cell culture for each experiment were estimated a priori via power 
analysis (power = 0.80, effect size = 0.25,  = 0.05) based on data generated in previous 
studies from our group. Mice were also randomized during collection to minimize batch 
effects. Data were analyzed using GraphPad Prism (La Jolla, CA). Statistical outliers were 
identified by the ROUT method (Q = 1%). Statistical significance (p < 0.05) between groups 
was determined via two-tailed Mann Whitney test. All p-values are reported in their 








2.2.1 Exposure to iAS does not change dietary intake or body weight 
 
Figure 3. Dietary intake and body weight throughout an eight-week, 615 μg/L iAS exposure 
in mice. Exposure to iAS does not change (a) food intake, (b) water intake, or (c) body 
weight in male or female mice (n = 10 mice per group). 
Food and water intake were monitored every two days throughout the duration of the 
exposure to ensure that cardiovascular pathologies, such as susceptibility to I/R injury, did 
not result from dietary restriction or dehydration.97 No significant differences were observed 







2.2.2 iAS induces sex-dependent increases in blood pressure and cardiac geometry 
 
Figure 4. Exposure to iAS induces sex-dependent increases in systolic blood pressure and left 
ventricular wall thickness. Systolic blood pressure (a) in females increases during the first 






0.0433) weeks of exposure, but subsequently returns to baseline. Systolic blood pressure (b) 
in males increases during the seventh (difference = 6.082 mmHg, *p = 0.0434) and eighth 
(difference = 9.207 mmHg, *p = 0.0350) weeks of exposure. Left ventricular anterior wall 
thickness in diastole (LVAWd) (c) in females does not change at weeks zero, four, or eight. 
However, LVAWd (d) in males increases at weeks four (*p = 0.0172) and eight (****p < 
0.0001). Left ventricular posterior wall thickness in diastole (LVPWd) (e) in females does 
not change at weeks zero, four, or eight. LVPWd (f) in males exhibits a trending increase at 
week four (p = 0.0812) and a significant increase at week eight (***p = 0.0002). Significance 
was determined by Mann Whitney test (n = 9 to 10 mice per group). 
 
Figure 5. Exposure to iAS induces sex-dependent hypertrophy of the heart. Left ventricular 
mass (LV mass) extrapolated from transthoracic echocardiography (a) in females does not 
change at weeks zero, four, or eight. LV mass (n = 10 mice per group), but (b) in males 
increases at the eighth week of exposure (difference = 12.58 mg, *p = 0.0350; n = 9 to 10 
mice per group). Heart mass normalized to tibia length (HM/TL) (c) in females does not 






hearts per group). Plasma atrial natriuretic peptide (ANP) (e) does not change in females (n 
= 10 mice per group), but (f) increases in males (*p = 0.0379; n = 9 to 10 mice per group). 
Plasma brain natriuretic peptide (BNP) does not change in either (g) females (n = 10 mice 
per group) or (h) males (n = 9 to 10 mice per group). Outliers were determined by the 
ROUT method (Q = 1%) and significance was determined by Mann Whitney test. 
We previously reported that a four-week exposure to 1000 μg/L of iAS was sufficient to 
exacerbate myocardial I/R injury in females, but not in males. Furthermore, we found that 
interventricular septal wall thickness was increased in female hearts at the four-week 
endpoint. Considering the possibility that iAS imparts sex-disparate effects on the structure 
and function of the heart, and that these effects change over an extended model of exposure, 
transthoracic echocardiography was conducted at zero, four, and eight weeks of iAS 
exposure (measured to be 614.6 μg/L in the current study), and blood pressure was recorded 
throughout. Systolic blood pressure was significantly increased in iAS-exposed females 
during the first and second weeks of exposure (+9.617 and +6.810 mmHg, respectively), but 
subsequently regressed back to baseline (Fig. 4a). Systolic blood pressure in iAS-exposed 
males, however, significantly increased at the seventh and eighth weeks of exposure (+5.962 
and +9.162 mmHg, respectively) (Fig. 4b). Consistent with this increase in systolic blood 
pressure in iAS-exposed males, we also found that anterior and posterior wall thickness was 
increased at eight weeks of exposure (Figs. 4d, f). Echocardiographic parameters in females, 
however, did not significantly change at either four or eight weeks of exposure (Figs. 4c, e). 
Additionally, left ventricular mass extrapolated from echocardiography showed an increase at 
the eight-week endpoint in males but not in females (Figs. 5a, b). As such, additional markers 
of a hypertrophic phenotype were probed. Heart weight normalized to tibia length was 






(Figs. 5e, f). Although plasma BNP levels did not change in either sex (Figs. 5g, h), these 
data, taken together, indicate that exposure to iAS induces sex-dependent hypertrophy of the 
heart. 
2.2.3 Exposure to iAS does not alter susceptibility to ischemic heart injury 
 
Figure 6. Exposure to 615 μg/L iAS for eight weeks does not alter susceptibility to ischemic 
heart injury. Langendorff-cannulated male and female hearts did not show changes in (a, e) 
baseline heart rate, (b, f) baseline contractility, quantified by a change in left ventricular 
developed pressure as a function of change in time (dP/dt), (c, g) post-ischemic functional 
recovery at 60 minutes into perfusion, and (d, h) post-I/R myocardial infarct size (n = 10 






To determine whether iAS-induced hypertrophy consequently altered myocardial ischemic 
susceptibility, several hemodynamic parameters were examined using an ex vivo model of I/R 
injury. Cardiac remodeling is an independent risk factor for adverse CV outcomes, and 
chronic iAS exposure has been particularly well-associated with ischemic heart disease.98–
103,92,72 Furthermore, a previous study from our group highlighted increased I/R injury in 
remodeled female hearts after a 1000 μg/L iAS exposure for four weeks.79 As such, it was 
hypothesized that cardiac hypertrophy would increase I/R injury. Male and female hearts 
were thus subjected to I/R injury via Langendorff perfusion after the eight-week exposure 
period. Hemodynamic measurements indicated no differences in baseline heart rate, left 
ventricular developed pressure, and rate pressure product between iAS-treated and control 
male or female hearts (data not shown). Additionally, contractility, functional recovery, and 
infarct size did not change with iAS exposure in either sex (Fig. 6). As such, an eight-week 







2.2.4 iAS does not induce physiological hypertrophy or cardiac fibrosis 
 
Figure 7. Exposure to iAS does not induce cardiac fibrosis. Masson’s Trichrome histology 
does not reveal changes in collagen deposition in either (a) females (n = 10 hearts per 
group) or (b) males (n = 9 to 10 hearts per group). Myocardial mRNA transcript levels of 
collagen type I alpha 2 chain (Col1a2) did not change in either (c) females or (d) males. 
Myocardial mRNA transcript levels of collagen type III alpha 1 (Col3a1) also did not change 
in either (e) females or (f) males (n = 10 hearts per group). Transcript levels of each target 
were normalized to Gapdh mRNA expression, which did not change with iAS exposure in 
either sex. Outliers were determined by the ROUT method (Q = 1%) and significance was 








Figure 8. Exposure to iAS does not induce physiological hypertrophy in the heart. Protein 
expression of phosphorylated Akt (p-Akt) at serine 473 normalized to total Akt protein 
levels did not change in the (a) male and (d) female heart (n = 5 hearts per group). Protein 
levels of t-Akt did not change in the (b) male and (e) female heart (n = 5 hearts per group). 
Myocardial mRNA transcript levels of Akt1 did not change in (c) males or (f) females (n = 
10 hearts per group). Protein levels of each target were normalized to total transferred 
protein levels. Transcript levels of each target were normalized to Gapdh mRNA expression, 






Because several studies have shown that iAS activates the TGF-β/Smad pathway and 
induces fibrosis in mice and rats, this investigation probed the possibility that the 
hypertrophic phenotype is driven by myocardial fibrosis.104 Masson’s Trichrome staining for 
collagen deposition, however, did not reveal an increase in fibrosis with iAS exposure in 
either sex (Figs. 7a, b). Additionally, this was confirmed by measuring mRNA expression of 
pro-fibrogenic extracellular matrix genes Col1a2 and Col3a1, for type I and type III collagen, 
respectively, which showed no significant changes (Figs. 7c – f). Since there was no evidence 
that the phenotype was driven by myocardial fibrosis, the possibility that iAS induces 
physiological hypertrophy of the heart was probed. Akt is downstream of several signaling 
pathways known to facilitate developmental growth of the myocardium, and as such, Akt 
phosphorylation levels at serine 473, an activating site, total Akt protein levels, and Akt RNA 
transcript levels were probed in male and female hearts (Fig. 8). However, there were no 
significant changes in either sex, indicating that an eight-week exposure to 615 μg/L iAS is 







2.2.5 Exposure to iAS induces pathological hypertrophy in the male heart 
 
Figure 9. Exposure to iAS induces markers of pathological hypertrophy in the heart. 
Myocardial mRNA transcript levels of (a) skeletal muscle alpha-actin (Acta1) increases (**p 
= 0.0037), (b) beta myosin heavy chain (Myh7) increases (*p = 0.0138), (c) alpha myosin 
heavy chain (Myh6) decreases (***p = 0.0001), (d) natriuretic peptide A (Nppa) increases 
(***p = 0.0001), and (e) natriuretic peptide B (Nppb) does not change in males. However, 
mRNA expression of (f) Acta1, (g) Myh7, (h) Myh6, (i) Nppa, and (j) Nppb does not change 
in female hearts. Transcript levels of each target were normalized to Gapdh mRNA 
expression, which did not change with iAS exposure in either sex. Outliers were determined 
by the ROUT method (Q = 1%) and significance was determined by Mann Whitney test (n 






Determination of whether iAS induces maladaptive growth of the myocardium was achieved 
by probing for downstream transcriptional markers of pathological hypertrophy. RT-qPCR 
revealed that mRNA expression of several genes coupled to pathological hypertrophy were 
increased with iAS exposure in males and not in females. Skeletal muscle alpha-actin (Acta1) 
and beta myosin heavy chain (Myh7) transcript levels exhibited an increase with exposure in 
males and not in females (Figs. 9a, b, f, g), and alpha myosin heavy chain (Myh6) showed a 
decrease in males and not in females, indicating an isoform switch (Figs. 9c, h). Additionally, 
natriuretic peptide A (Nppa) mRNA was significantly increased in males and not in females, 
while no change was observed in natriuretic peptide B (Nppb) transcript (Figs. 9d, e, i, j), 







2.2.6 Further exposure to iAS may cause female hearts to lose protection 
 
Figure 10. Exposure to iAS may alter PKG signaling in the heart. Male hearts exhibited (a) 
no changes in PKG protein expression, (b) increased protein expression of total vasodilator-
stimulated phosphoprotein (t-VASP) (*p = 0.0159), and (c) decreased protein expression of 
phosphorylated VASP (p-VASP) at serine 239, a PKG site, normalized to t-VASP (*p = 
0.0317). Female hearts exhibited (d) a decrease in PKG protein expression near significance 
(p = 0.0556), and (e) no changes in p-VASP. Protein levels of each target were normalized 
to total transferred protein levels. Outliers were determined by the ROUT method (Q = 1%) 







Figure 11. Exposure to iAS does not alter NO signaling in the heart. Male hearts exhibited no 
changes in (a) protein levels of total endothelial nitic oxide synthase (t-eNOS), (b) protein 
levels of phosphorylated eNOS at serine 1177, an activating site, (p-eNOS) normalized to t-
eNOS, (c) protein levels of p-eNOS at threonine 495, an inhibitory site, normalized to t-
eNOS, (d) cardiac reactive oxygen species (ROS) levels, and (e) protein levels of neuronal 
NOS (nNOS). Female hearts also did not exhibit any changes in (f) t-eNOS, (g) p-eNOS 
(S1177) / t-eNOS, (h) p-eNOS (T495) / t-eNOS, or (i) cardiac ROS, but (j) nNOS protein 
levels were decreased (*p = 0.0159). Protein levels of each target were normalized to total 
transferred protein levels. Outliers were determined by the ROUT method (Q = 1%) and 
significance was determined by Mann Whitney test (n = 5 hearts per group). 
Since females did not demonstrate a hypertrophic phenotype following an eight-week iAS 
exposure, potential mechanisms underlying the observed protection were investigated. 






difference with iAS in males, but there was a significant decrease in females, suggesting a 
potential root to an eventual pathology in females (Figs. 10a, d). Protein levels of vasodilator 
stimulated protein (VASP) were significantly increased in males with iAS exposure (Fig. 
10b), in accordance with the increase in systolic blood pressure, and protein levels of 
phosphorylated VASP at serine 239, a PKG site, were decreased in males but not in females, 
suggesting that PKG signaling may be impaired in males as part of the mechanisms leading 
to cardiac remodeling (Figs. 10c, e). Additionally, it was hypothesized that endothelial nitric 
oxide synthase (eNOS) may be upregulated in females and either downregulated or 
uncoupled in males, thus modulating the sex-dependent hypertrophic response. However, 
western blots for total eNOS, phosphorylated eNOS at serine 1177, an activating site, and 
phosphorylated eNOS at threonine 495, an inhibitory site, did not reveal significant changes 
with iAS exposure in either sex (Figs. 11a, b, c, f, g, h). Total iNOS protein levels were also 
probed but bands were not detected (data not shown). Myocardial superoxide levels were 
measured as a marker of eNOS uncoupling in heart homogenate via EPR, but iAS did not 
induce a change in superoxide production in either sex (Figs. 11d, i). Although protein levels 
of total nNOS were unchanged in iAS-exposed males, these levels were significantly 
decreased in iAS-exposed females (Figs. 11e, j). Seeing as the protein levels of both PKG 
and nNOS were significantly decreased in the female heart, these data suggest the potential 







2.2.7 iAS activates NFAT independent of blood pressure 
 
Figure 12. Exposure to iAS may activate the calcineurin-NFAT signaling pathway. Protein 
expression of calcineurin A were unchanged in (a) male and (b) female hearts (n = 5 hearts 
per group). Myocardial mRNA transcript levels of regulator of calcineurin 1 (Rcan1) were (c) 
unchanged in females, but (d) increased in males (*p = 0.0161) (n = 10 hearts per group). 
HEK293 cells treated with varying levels of iAS for 24 hours demonstrate (e) cell 
proliferation, represented by optical density as a percent of the average control, following a 
dose-response curve (n = 12 wells per group). HEK293 cells transfected with NFAT-
luciferase and Renilla-luciferase, as well as Trpc6 for a positive control (+), exhibited (f) 






= 8 wells per group). Protein levels of each target were normalized to total transferred 
protein levels. Transcript levels of each target were normalized to Gapdh mRNA expression, 
which did not change with iAS exposure in either sex. NFAT firefly luminescence was 
normalized to Renilla luminescence. Outliers were determined by the ROUT method (Q = 
1%) and significance was determined by Mann Whitney test. 
Considering that the calcineurin-NFAT signaling pathway is known to be upregulated with 
pathological and not physiological cardiac hypertrophy, total Calcineurin A protein levels in 
the heart were measured as a crude surrogate for calcineurin-NFAT activation, but these 
levels did not change with exposure in either sex (Figs. 12a, b). RT-qPCR, however, revealed 
that mRNA expression of regulator of calcineurin 1 (Rcan1), an NFAT target, was 
upregulated in iAS-exposed males and not in females (Figs. 12c, d), suggesting iAS may 
induce pathological hypertrophy of the heart in part by activation of calcineurin-NFAT. 
Taking blood pressure and echocardiography data into account, which characterized a 
significant increase in anterior and posterior wall thickness in males at four weeks of 
exposure prior to the observed increase in systolic blood pressure at weeks seven and eight, 
an in vitro exposure model was established to determine whether iAS can activate NFAT and 
induce hypertrophy independent of input from blood pressure. HEK293 cells were treated 
with varying concentrations of iAS for 24 hours, and an MTT cell proliferation assay 
revealed a dose-response curve with 50 μM iAS generating half-maximal proliferation (Fig. 
12e). HEK293 cells transfected with an NFAT-luciferase reporter showed that NFAT 
luciferase activity significantly increased with a 1 μM iAS treatment for 24 hours, indicating 
that iAS directly induces the activation of NFAT, independent from blood pressure, as 
hypothesized (Fig. 12f). Together, these data suggest that iAS may activate calcineurin-







Epidemiological studies have associated chronic iAS exposure with the development of 
cardiovascular disease, and recent findings highlight an association with altered left 
ventricular geometry.103,91–93 Herein, we find that exposure to an environmentally relevant 
dose of iAS through drinking water induces pathological hypertrophy of the heart in male 
mice but not females. We also report for the first time that iAS may induce these changes 
independent of blood pressure and fibrosis, in part by activating the calcineurin-NFAT 
signaling pathway. 
Several epidemiological studies highlight an association between iAS exposure and both an 
increased systolic blood pressure in both biological sexes and an increased prevalence ratio 
for hypertension.75,76,105–109 Experimental studies corroborate this increase in systolic blood 
pressure in both male rats exposed to 50 mg/L iAS for 28 weeks, and female mice exposed 
to 100 μg/L iAS for 22 weeks.74,110 However, mechanistic studies also find that the effect of 
a chronic, low-level iAS on blood pressure often differs from that of higher levels.104 Here, 
systolic blood pressure was significantly increased in female mice exposed to 615 μg/L iAS, 
measured to be 615 μg/L via ICP-MS, during the first and second weeks of exposure, but 
this increase returned to baseline through the eighth week (Fig. 4a). Considering that a 
previous study has reported an increase in systolic blood pressure in female mice following a 
longer exposure, and that iAS is not reported to induce a sex-disparate phenotype in the CV 
system at the epidemiological level, systolic blood pressure between iAS-treated and control 
female mice is expected to diverge with an extended model of exposure. Systolic blood 
pressure in males, on the other hand, increased at the seventh and eighth weeks of exposure 






increased with iAS exposure as measured at the eighth week, altogether demonstrating that 
iAS exposure induces cardiac remodeling (Figs. 4d, f). 
Further examination of biological markers substantiated an iAS-induced hypertrophic 
phenotype in males and not in females. Left ventricular mass extrapolated from 
echocardiography increased with iAS in males at the eighth week, yet there was no change 
with iAS in females (Figs. 5a, b); this was confirmed by heart mass normalized to tibial 
length (Figs. 5c, d).111 Plasma levels of atrial natriuretic peptide (ANP), which is stimulated 
by mechanical stretch of the atrial wall and is upregulated in cardiac hypertrophy, were 
increased in iAS-exposed males and not in females (Figs. 5e, f).112 Plasma levels of B-type 
natriuretic peptide (BNP), however, which is also upregulated under hypertrophy, did not 
change with iAS exposure in either sex (Figs. 5g, h).113 While ANP and BNP both promote 
anti-hypertrophic actions, the former primarily regulates cardiomyocyte size and blood 
pressure/volume, and the latter regulates cardiac fibrosis, in part by inhibiting the 
transforming growth factor-β (TGF-β) signaling pathway.114–117 Quantification of myocardial 
collagen by image analysis showed no difference in cardiac fibrosis with iAS exposure in 
either sex, in accordance with plasma BNP levels (Figs. 3a, b). Additionally, measurement of 
Col1a2 and Col3a1 mRNA in the myocardium confirmed that iAS exposure did not 
upregulate TGF-β-responsive extracurricular matrix genes to induce cardiac fibrosis (Figs. 7c 
– f).118,119 Although experimental literature has well-characterized that iAS can activate the 
TGF-β pathway to induce the fibrosis of several organs, including the heart, liver, and lung, 
these studies used significantly greater concentrations than that used in the current study.104 
We therefore probed previously uninvestigated mechanisms through which a chronic, low-






Both physiological and pathological biomarkers were probed, revealing that iAS induces 
pathological hypertrophy of the heart.  Epidemiological evidence does not suggest that iAS 
confers CV benefits, but echocardiography-derived ejection fraction, fractional shortening, 
and cardiac output did not change at this eight-week timepoint (data not shown).79 As such, 
the possibility of physiological growth was examined. Akt is a downstream regulator of 
several critical processes involved in adaptive hypertrophy, including cell proliferation, 
growth, metabolism, and survival, and many studies have shown that iAS activates Akt 
through a variety of mechanisms in the context of carcinogenesis.21,120–126 Levels of 
phosphorylated Akt protein at serine 473, an activating site, total Akt protein, and Akt 
mRNA were thus measured in the myocardium. However, these levels did not change with 
iAS exposure in either sex, suggesting that iAS exposure does not induce physiological 
growth of the heart (Fig. 8). Myocardial expression of a suite of genes upregulated in 
pathological hypertrophy was subsequently examined. Skeletal muscle alpha-actin, Acta1, 
increases in the hypertrophied heart and is associated with cardiac dysfunction.127–129 RNA 
sequencing data also reveal that Acta1 is differentially upregulated in pathological versus 
physiological hypertrophy.130 Exposure to iAS increased Acta1 mRNA expression in male 
and not female hearts, in accordance with the hypothesis that iAS induces pathological 
hypertrophy (Figs. 9a, f). Myosin heavy chain undergoes an isoform shift from its alpha 
form, Myh6, to its beta form, Myh7, in the stressed, hypertrophied, and failing hearts.131–133 
Myocardial mRNA levels of Myh7 and Myh6 were increased and decreased, respectively, with 
iAS exposure in male hearts, and no changes were observed in female hearts, further 
demonstrating that iAS induces pathological hypertrophy (Figs. 9b, c, g, h). Additionally, 
myocardial mRNA transcripts for ANP, Nppa, and BNP, Nppb, which are upregulated in 






levels found in plasma (Figs. 5d, e, i, j). Taken together, these data reveal that iAS exposure 
induces pathological hypertrophy in the male heart. 
To determine whether iAS-induced hypertrophy consequently alters myocardial ischemic 
susceptibility, several hemodynamic parameters were examined using an ex vivo model of I/R 
injury. Cardiac remodeling is an independent risk factor for adverse CV outcomes, and 
chronic iAS exposure has been particularly well-associated with ischemic heart disease.98–
103,92,72 Furthermore, a previous study from our group highlighted increased I/R injury in 
remodeled female hearts after a 1000 μg/L iAS exposure for four weeks.79 As such, it was 
hypothesized that pathological hypertrophy of heart would increase I/R injury. Male and 
female hearts were thus subjected to I/R injury via Langendorff perfusion after the eight-
week exposure period. However, baseline heart rate, left ventricular developed pressure, 
contractility, and rate pressure product, as well as post-I/R functional recovery and infarct 
size did not significantly change with iAS exposure in either sex (Fig. 6). Although iAS-
induced pathological hypertrophy did not predispose the male heart to exhibit increased 
susceptibility to I/R injury, it is possible that this phenotype modulates other CVD risk 
factors and endpoints, such as QT interval, which have been epidemiologically observed in 
chronically-exposed populations.77,134,135 Beyond adverse cardiovascular outcomes in the 
exposed myocardium, and seeing as several iAS-upregulated transcripts found in this study 
belong to the fetal gene program, it’s interesting to speculate whether a gestational exposure 
to iAS delays the transition of sarcomeric, metabolic, and contractile proteins into adult 
isoforms in the postnatal heart to either predispose or induce congenital disease.136–138 
Considering that iAS-exposed female hearts did not demonstrate cardiovascular pathology 






mechanisms that may be responsible for the observed protection. Nitric oxide, produced by 
endothelial, neuronal, and inducible nitric oxide synthase (eNOS, nNOS, iNOS), serves not 
only as a signaling molecule in myocardial function, but also as a sex-dependent regulator of 
myocardial remodeling.17,39,54,139–143 While eNOS inhibition is shown to induce hypertrophy, 
abrogated by its restoration, its overexpression is shown to attenuate hypertrophy.43,44 
Furthermore, the antihypertrophic effects of NO manifest in part by cGMP-mediated 
activation of PKG, which can act through a variety of mechanisms to suppress NFAT 
transcriptional activity in the myocardium.21,45,120 Although literature has shown that iAS acts 
as an endocrine disruptor, some evidence suggests that certain very low doses may 
upregulate estrogen-mediated gene expression, and as such, it was hypothesized that 
endogenous female cardioprotection was enhanced by iAS exposure at this timepoint as a 
quirk of the exposure model.144 Protein levels of total eNOS and phosphorylated eNOS at 
S1177, an activating site, did not change with iAS exposure in either sex (Fig. 11). eNOS 
phosphorylation at T495, an inhibitory site, was decreased in iAS-exposed females, but the 
increase was not significant when normalized to total eNOS levels (Fig. 11). Additionally, 
phosphorylation of vasodilator-stimulated phosphoprotein (VASP) at S239, a PKG site, was 
differentially increased in iAS-exposed females and not in males, but this similarly did not 
maintain significance when normalized to total VASP levels (Figs. 10). However, the protein 
levels of PKG and nNOS significantly decreased with iAS exposure in female hearts (Figs. 
10, 11). As such, these data suggest that PKG signaling may be impaired as part of the 
mechanism leading to iAS-induced cardiac remodeling in males, while in females, PKG 
signaling may be impaired beyond an eight-week exposure. 
Further investigation probed upstream mechanisms of how iAS may induce pathological 






for 12 weeks induces systemic hypertension in male rats by increasing the expression of 
angiotensin II, angiotensin II type I receptor, and angiotensin-converting enzyme.145 
Subsequently, they showed that blocking the receptor ameliorated iAS-induced hypertension 
and TGF-β-mediated fibrosis.146 However, considering that current study of an eight-week, 
615 μg/L iAS exposure did not find any evidence of myocardial fibrosis, the possibility that 
iAS directly induces hypertrophy, beyond angiotensin II signaling, was explored. Calcineurin-
NFAT signaling is shown to be both necessary and sufficient to induce pathological cardiac 
hypertrophy.21,30,120,147 Protein levels of Calcineurin A, the catalytic subunit of the serine-
threonine phosphatase, were measured in the myocardium as a crude surrogate for 
calcineurin-NFAT activation. However, these levels were unchanged with iAS exposure in 
both sexes (Figs. 12a, b). Regulator of calcineurin 1, Rcan1, is an inhibitor of calcineurin A 
that’s upregulated with calcineurin-NFAT activation in a negative feedback loop.148,149 
Measuring its mRNA expression revealed that iAS exposure significantly increased Rcan1 in 
the male heart and not in females, in accordance with the phenotype, suggesting that iAS 
may induce pathological cardiac hypertrophy in part by upregulating the calcineurin-NFAT 
pathway (Figs. 12c, d). 
An in vitro model of exposure was established to determine whether iAS activates 
calcineurin-NFAT signaling independent of blood pressure. Previous studies that have 
investigated the effects of iAS in vitro have determined that the low-level concentrations used 
for the luciferase assay in the current study increase transcription factor activation and 
induce gene expression without causing cytotoxicity.150,151 An MTT cell proliferation assay 
confirmed the latter (Fig. 12e). Considering that males presented a significantly increased left 
ventricular anterior wall thickness as well as an increased posterior wall thickness trending 






systolic blood pressure, it was hypothesized that iAS can directly induce cardiac hypertrophy. 
HEK293 cells were transfected with an NFAT-luciferase reporter and plasmids expressing 
transient receptor potential canonical type 6 (Trpc6) and/or Renilla-luciferase as positive and 
internal controls, respectively.152,153 Treatment with 1 μM iAS significantly increased NFAT 
luciferase activity, suggesting that iAS has the potential to induce pathological hypertrophy, 
independent of blood pressure, through the calcineurin-NFAT pathway (Fig. 12f). Although 
it appeared that iAS-induced activation of NFAT was biphasic, where 1 μM iAS induced 
luciferase activity similar to that of the positive control while greater concentrations reduced 
activity to baseline, previous studies have demonstrated that iAS has an analogous 
bidirectional, concentration-dependent role in TGF-β/Smad signaling, highlighting 
nonlinearity underlying the mechanisms of iAS-induced pathology.104 Taken together, these 
data suggest that iAS may directly induce pathological cardiac hypertrophy. 
iAS has been shown to activate several transcription factors, including nuclear factor 
erythroid 2-related factor 2 (Nrf2), nuclear factor kappa B (NF-κB), and activating protein-1 
(AP-1).154 Whereas iAS-induced activation of Nrf2 is primarily mediated by the production 
of reactive oxygen species (ROS), its activation of NF-κB is mediated by both ROS and 
direct binding of reactive thiols on the inhibitory Keap1 protein.155 Additionally, iAS has 
been shown to directly bind zinc finger motifs as well as the AP-1-like transcription factor 
Yap8, coordinating three critical cysteines to induce an activating conformational 
change.155,156 Considering that NFAT is activated by an array of factors, including by proteins 
with zinc and cysteine-rich domains, by crosstalk with NF-κB, by direct interaction with AP-
1, and by ROS, it is beyond the scope of this study to determine the exact iAS-modulated 
alterations that mediate the hypertrophic response.157–163 However, it is possible to speculate 






(a) interactions between iAS or an electrophilic iAS metabolite with a reactive thiol of the 
transcription factor complex, (b) cooperative interactions between NFAT and other 
transcription factors, and/or (c) oxidative stress. 
2.3.1 Limitations 
Indeed, this investigation should be considered in the context of its strengths and 
weaknesses. Although the model of exposure used here doubled the duration of a previous 
study from our laboratory, the divergence in systolic blood pressure during the last two 
weeks in iAS-treated males, paired with the lack thereof in females, highlights not only the 
temporal nature of the CV effects of iAS exposure, but also the limitation of not capturing 
all such effects in an eight-week study; as such, a longer duration is recommended for future 
investigations.79 Additionally, blood pressure was measured using photoplethysmography via 
tail cuff, which provides indirect readings and serves as another area of potential weakness. 
However, this tool has been validated for accuracy and reliability by independent study, and 
it provided sufficient data to extrapolate relative trends, at the least.164,165 Direct recording of 
blood pressure via radiotelemetry is a standard that may be used in future studies, given the 
justification for surgery; this would circumvent the need for restraint and provide continuous 
measurements with improved accuracy throughout the exposure period.165 Moreover, while 
transthoracic echocardiography was conducted at three timepoints throughout this study, 
additional measurements would provide further resolution. Lastly, the determination of 
whether iAS-induced hypertrophy altered susceptibility to I/R injury may have utilized an in 
vivo model by surgical occlusion of the left anterior descending coronary artery. Seeing as the 
present study did not find any alterations in ischemic heart injury, it is recommended that 






is observed in both sexes. Additionally, considering the possibility that a chronic, low-level 
iAS exposure beyond eight weeks induces cardiac hypertrophy and systemic hypertension in 
both sexes, an optimized exposure model may then investigate the iAS-induced modulation 
of risk factors to promote CVD pathogenesis. 
Notably, this study leverages findings rooted in human populations and begins to unravel a 
mechanistic understanding using mouse and cell culture systems—an advantage that is also 
inherently limited by interspecies differences, and as such, the relevance and discrepancy 
between model systems must be addressed. Animal models provide controlled, organism-
level model systems that help evaluate the pathophysiology of environmental exposures by 
first ideally recapitulating epidemiological phenotypes. Although the iAS dose used in the 
current study is found among the greater concentrations of exposure in human populations, 
there exist differences in the methylation and biotransformation of iAS between humans and 
mice, as well as differences in its rate of excretion, which constructs discrepancies in iAS 
metabolism and thus the mechanisms of action that may lead to the observed pathologies.166 
Mice demonstrate greater iAS biotransformation and excretion rates compared to humans, 
but since the difference of the former has been shown to diminish at greater concentrations 
of iAS in mice compared to humans, it is possible that a mouse exposure to 615 μg/L iAS 
may induce the effects observed at lower concentrations in humans.166 Overall, considering 
that cardiac hypertrophy was observed in the male mouse heart, the mouse exposure model 
was phenotypically-relevant, in accordance with echocardiography data in humans. Future 
studies may thus seek to validate these findings in other animal models, such as rats or 
rabbits, which exhibit even greater rates of iAS biotransformation. Additionally, background 
co-morbidities such as a high-fat diet, atherosclerosis via apolipoprotein E knockout, or 






relevant risks in human populations, and co-exposures such as other metals or air pollutants 
may be introduced in order to serve as a more environmentally-relevant model, altogether 
serving as modes for future investigations examining iAS and the cardiovascular system. 
Evaluating the relevance of iAS exposure in a cell culture model is particularly challenging, 
but the model justifiably served the purpose in the current study to determine whether iAS 
can activate NFAT independent of an elevation in blood pressure. Cell proliferation was 
evaluated in order to determine iAS toxicity and ensure that the effects observed were not 
due to the processes of cell death; this MTT assay (0, 0.5, 1, 5, 10, 25, 50, 100 uM; n = 12 
wells/group) revealed that 1 uM iAS treatment for 24 hours did not alter cell proliferation. 
Additionally, several low-level iAS concentrations were utilized in the luciferase assay, all of 
which have been evaluated to induce human-relevant expression of oxidative stress genes 
using the same cell line.151 Furthermore, iAS-induced gene expression at these concentrations 
in this cell line has been shown to remain unchanged between six and 24-hour exposures, 
such that the NFAT activation in the present study is likely not an artifact of time.151 As 
such, the novel finding that 1 μM iAS activates NFAT in vitro is valid. However, HEK293 
cells are derived from human embryonic kidney epithelium, and although these were 
specifically chosen to yield improved transfection efficiency, they do not share the same 
proteomic and metabolomic profile compared to cardiomyocytes, and as such, the effect of 
iAS exposure on the activation of NFAT may be different in the heart. Future studies may 
thus utilize either a H9C2 rat-derived embryonic cardiac myoblast cell line, which is 
commercially available, or primary cardiac cells such as neonatal/adult cardiomyocytes or 
embryonic fibroblasts, isolated from mice, in order to more closely replicate an in vivo model 
of iAS exposure in the myocardium. Additionally, whereas cells were directly treated with 






cardiomyocytes may differ in the concentration and/or the metabolite that reaches the heart 
in mice and humans. Future experiments may thus leverage the novel finding that exposure 
to iAS induces NFAT activity in vitro and further tease out this mechanism by utilizing in vitro 
inhibitors of calcineurin and ROS, among other upstream NFAT activators in order to 
reduce iAS-induced NFAT transcription back to baseline. Future studies can also provide 
stronger evidence as to whether iAS exposure in vivo directly induces this signaling pathway 
by utilizing a cardiac-specific NFAT-luciferase reporter mouse. Taken together, since the 
upregulation of several NFAT targets was observed, in addition to the expected phenotype, 
there exists justification with the data presented in the current study that iAS exposure may 
induce cardiac hypertrophy in the mouse heart, at least in part by direct activation of the 
NFAT pathway. 
2.3.4 Conclusions 
Overall, this is the first mechanistic investigation examining an environmentally relevant iAS 
exposure on the development of cardiac hypertrophy in male and female mice. During our 
eight-week exposure, males showed an increase in systolic blood pressure and altered cardiac 
geometry, while females appeared to remain protected from such effects. iAS treatment 
induced an array of molecular changes indicating pathological hypertrophy in the male heart, 
and these were not detected in female hearts. Further data support the novel finding that iAS 
induces pathological hypertrophy of the heart in part by activation of the calcineurin-NFAT 
pathway. Taken together, this investigation provides a mechanistic link between an 
environmentally relevant iAS exposure, the induction of pathological hypertrophy, and the 
increased the risk for adverse CV outcomes. Ultimately, these findings underscore the 






2.3.4 Translational Impact 
This study complements clinical findings by highlighting the direct pathophysiological 
impact of an environmental exposure to iAS on the cardiovascular system. By demonstrating 
that iAS exposure may cause pathological cardiac hypertrophy by increasing systolic blood 
pressure, potentially activating calcineurin-NFAT, and inducing the fetal gene program, these 
results provide novel mechanistic insight into the threat of iAS exposure to the heart, which 
is necessary to identify targets for medical and public health intervention. 
 
Figure 13. Exposure to iAS induces sex-dependent pathological hypertrophy of the heart. 










3.1 Optimize the Model of Exposure 
Rather than delving into the sex difference characterized in this study and attempting to 
elucidate a transient mechanism of female cardioprotection, though a notable investigation, 
future experiments should first and foremost extend the duration of exposure such that 
cardiac pathology is observed in both males and females as reflected in epidemiological 
findings. Beyond duration, the present study provides insight into concentrations that should 
be used in future studies. Results from the luciferase assay suggest that iAS has a biphasic, 
concentration-dependent effect on NFAT activation. Additionally, the present study utilized 
observed hypertrophy with no evidence of fibrosis, in direct contrast to previous studies that 
used several-fold greater concentrations. As such, future studies should contemplate the use 
of an iAS dose significantly less than 615 μg/L for a longer duration, altogether optimizing 
an environmentally relevant model of exposure for use in studies investigating the effects of 
iAS exposure on the cardiovascular system. 
3.2 Characterize the Effects on Heart and Cardiomyocyte Physiology 
Beyond confirming elevated systolic blood pressure and cardiac remodeling in an optimized 
exposure model, it’d be particularly interesting to delve into the in vivo and in vitro physiology 
of the heart. Characterization of whether iAS exposure decreases myocardial contractility 
and chamber compliance, which are physiological properties expected in pathological 
hypertrophy and heart failure that cannot be measured via transthoracic echocardiography, 






Although this was considered for the present study, technical challenges outweighed the 
insight of the parameters obtained through these detailed hemodynamic measurements. 
Furthermore, it would be interesting to isolate cardiomyocytes from exposed and control 
mouse hearts to measure cardiomyocyte contractility and calcium handling. Epidemiological 
studies have established that iAS exposure is significantly associated with prolongation of the 
QT interval, which describes a delay between ventricular depolarization and 
repolarization.77,167 Mechanistically, this may be the result of an increase in sodium or calcium 
influx, or a decrease in potassium efflux. Experimental studies have found that iAS exposure 
increases intracellular calcium levels in vitro and alters in silico and in vivo expression of several 
calcium binding proteins regulating calcium homeostasis.168–170 As such, it may be worthwhile 
to determine whether cardiomyocytes isolated from iAS-exposed hearts exhibit altered 
calcium transients and shortening. By further characterizing the physiological properties of 
the iAS-exposed myocardium in vivo as well as the in vitro cardiac contractile effects of iAS 
exposure, future investigations may provide a deeper understanding of the mechanisms by 
which iAS exposure alters cardiovascular physiology to increase CVD susceptibility and 
pathogenesis. 
3.3 Define the Effects of Inorganic Arsenic on NFAT Activation 
Considering that the present study highlights the potential for calcineurin-NFAT activation 
in the induction of pathological hypertrophy, it is also logical to next define the mechanisms 
through which activation may manifest. Preliminary experimentation should characterize the 
phosphorylation and localization of NFAT and its isoforms as permitted by the antibodies 
available; a decrease in phosphorylation and an increase in nuclear localization is expected 






be worthwhile to probe the levels of negative calcineurin-NFAT regulators such as glycogen 
synthase kinase 3 beta, which phosphorylates NFAT to enhance its nuclear export and 
cytosolic localization. Upstream factors that may activate this signaling pathway center 
around increased intracellular calcium such that iAS-exposed hearts may exhibit increased 
modification of calmodulin target proteins. Furthermore, an in vitro approach to determine 
whether iAS activates NFAT by increasing intracellular calcium may be to observe whether 
iAS-treated H9C2 cardiac cells display NFAT luciferase activity with a calcium channel 
blocker. Separately, seeing as iAS may activate NFAT by promoting cooperativity with other 
iAS-activated transcription factors, by directly interacting with the transcription factor 
complex, or by inducing ROS, several additional in vitro approaches may be taken. Whether 
iAS induces cooperativity with other transcription factors such as NF-κB or AP-1 to activate 
NFAT may be determined by an electrophoretic mobility shift assay or a fluorescence 
resonance energy transfer experiment. Whether iAS directly interacts with NFAT to 
upregulate its targets may be determined by treating H9C2 cells with biotinylated iAS and 
running a pull-down with streptavidin to then identify via liquid chromatography MS/MS 
whether any NFAT isoforms are bound. Lastly, to determine whether ROS-mediated 
activation of NFAT is responsible for iAS-induced hypertrophy, NFAT luciferase activity in 
iAS-treated H9C2 cells may be observed in the presence of ROS scavengers. Indeed, an 
investigation to determine the mechanism by which iAS activates NFAT is complex, but any 
combination of these proposed experiments will provide critical insight into the effect of iAS 







3.5 Explore the Effects of Inorganic Arsenic on the Developing Heart 
Several iAS-upregulated transcripts found in the present study belong to the fetal gene 
program, and as such, it is interesting to speculate whether a gestational exposure to iAS 
delays the transition of sarcomeric, metabolic, and contractile proteins into adult isoforms in 
the postnatal heart to either predispose or induce congenital disease.136–138 Metabolism in the 
fetal heart leverages carbohydrates such as glucose, lactate, and glycogen as the primary 
substrate for energy, rather than fatty acids as used by the adult heart. Additionally, 
contractile physiology of the fetal heart is geared towards mechanical performance under 
fetal circulation and thus, for example, utilizes slow twitch muscle fibers rather than the fast 
twitch isoform found in the adult heart. Exposure to iAS is herein observed to induce a 
panel of myocardial mRNA transcripts that suggests a return to the fetal gene program. As 
such, a future study should determine whether a maternal exposure to iAS throughout 
pregnancy activates and prolongs the expression of these genes in both the fetal and 
postnatal heart. Perhaps the measurement of fetal gene expression across the developmental 
stages of the iAS-exposed heart through birth may indicate a delay the switch to expressing 
isoforms required in the adult heart, thereby priming the progeny for structural and 
metabolic abnormalities associated with an increased CVD susceptibility. Again, these 
experiments are technically challenging, but taken together, may provide novel 
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